home / stock / mnk / mnk news

MNK News and Press, Mallinckrodt plc From 05/22/23

Stock Information
Company Name: Mallinckrodt plc
Stock Symbol: MNK
Market: NYSE
Menu
MNK MNK Quote MNK Short MNK News MNK Articles MNK Message Board
Get MNK Alerts

News, Short Squeeze, Breakout and More Instantly...
MNK - ICPT, MNK and MBOT are among mid day movers

2023-05-22 12:55:14 ET Gainers: Microbot Medical  ( MBOT ) +132% . Greenhill & Co ( GHL ) +117% . Hepion Pharmaceuticals ( HEPA ) +64% . Akebia Therapeutics ( AKBA ) +39% . VectivBio Holding ( VECT ) +36% . Atea Phar...
MNK - Microbot Medical, Hepion Pharmaceuticals among healthcare gainers; Rain Oncology leads losers

2023-05-22 10:03:29 ET Gainers: Microbot Medical ( MBOT ) +46% . Hepion Pharmaceuticals ( HEPA ) +41% . Atea Pharmaceuticals ( AVIR ) +38% . VectivBio Holding ( VECT ) +37% . CNS Pharmaceuticals ( CNSP ) +23% . Losers: Rain Oncology ( ...

MNK - ICPT, MNK and TRMD are among pre market losers

2023-05-22 08:53:42 ET Rain Oncology ( RAIN ) +-82% Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma. Volcon ( VLCN ) +-30% slides after announcing new equity offering. Mallinckrodt ( MNK...

MNK - Lucy Scientific, Bioventus top healthcare gainers; Enveric, Elevation among losers

2023-05-19 10:04:48 ET Gainers: Lucy Scientific Discovery ( LSDI ) +51% . Bioventus ( BVS ) +44% . Mallinckrodt ( MNK ) +28% . 180 Life Sciences ( ATNF ) +28% . Stereotaxis ( STXS ) +25% . Losers: Enveric Biosciences ( ENVB ...
MNK - Mallinckrodt plc (MNK) Q1 2023 Earnings Call Transcript

2023-05-09 11:50:05 ET Mallinckrodt plc (MNK) Q1 2023 Earnings Conference Call May 09, 2023 8:30 AM ET Company Participants Dan Speciale – Chief Investor Relations Officer Siggi Olafsson – Chief Executive Officer Bryan Reasons – Chief Financi...

MNK - Mallinckrodt Non-GAAP EPS of $1.68, revenue of $424.6M

2023-05-09 06:49:16 ET Mallinckrodt press release ( NYSE: MNK ): Q1 Non-GAAP EPS of $1.68. Revenue of $424.6M (-13.5% Y/Y). FY23 Outlook: Revenue of $1.7B-$1.82B Adj EBITDA of $510M-$560M For further details see: Mallinckrodt Non-GAAP EPS of $1.68, revenu...

MNK - Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance PR Newswire Advanced Launch of Terlivaz ® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarte...
MNK - Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023

Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023 PR Newswire – Findings from two clinical study presentations in adults with HRS involving rapid reduction in ...

MNK - Earnings Week Ahead: Fox Corporation, Disney, Airbnb, and more

2023-05-05 14:00:36 ET Earnings season continues next week, although the pace of releases begins to slow. Entertainment companies provide key highlights during the period, with reports due out from Disney ( DIS ) and Fox ( FOX ). Outside of media, both the pharmaceutical and EV ...

MNK - Buxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding Failure to Address Evidential Multibillion-Dollar Asset Value Depreciation Expense Concealment Scheme

The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (NYSE: MNK), toda...
Previous 10 Next 10